Home > Press > HORIBA Medical and CEA-Leti Strengthen Their Partnership to Develop Tomorrow’s Diagnostics at the Point of Care
Abstract:
HORIBA Medical, a subsidiary of Japan-based HORIBA Group, the global leader for measurement and analysis systems, has been designing, manufacturing and marketing high performance analyzers for laboratories and hospitals for over 30 years. This expertise that has made the company one of the world leaders in Hematology and a key player in the Hemostasis and Clinical Chemistry activity.
Today, patient care and treatment practices are evolving quickly. HORIBA Medical is designing solutions to anticipate patient-centered needs by developing new POCT (Point of Care Testing) systems.
In parallel, for the past six years HORIBA Medical has been working with one of the most innovative organizations in the field of new technologies, CEA-Leti, the technology research laboratory of CEA Tech, federating their respective skills in a Joint Laboratory called HEMACOUNT.
“We focused on two disruptive technologies: a microfluidic cartridge and a new, lens-free imaging device (LensFree), which will enable development of more compact, easier-to-use POCT-type devices,” says Damien Isebe, who heads up this highly innovative project at HORIBA Medical. “Twelve families of patents have been filed since the start of the project, and the latest one has been the subject of several scientific papers”.
“Flow cytometry is the main analytical technology in hematology, but it requires large and complex hardware systems. Conversely, lens-free imaging combined with a sample prepared as a microfluidic cartridge paves the way to a simple and compact disruptive architecture. This imaging technique provides a wide field of view (≈30mm˛) resulting in a counting statistic (a few thousand cells) in one single acquisition consistent with required hematological performance,” explains Sophie Morales, laboratory head at CEA-Leti.
The latest publications and presentations to date: for LensFree, one publication in the Journal of Biomedical Optics and two oral presentations at ECBO (European Conferences on Biomedical Optics), held in Munich in late June 2019; and for the work on microfluidics, presentation of a scientific poster at µTAS (International Conference on Miniaturized Systems for Chemistry and Life Sciences) in Basel, Switzerland, in October 2019.
Given the success of the partnership and the work that remains to be done, HORIBA Medical is pleased to announce the continuation of this collaboration, which will allow it to draw value from this work in the form of innovative applications, to bring developments to maturity and to design products that will serve care-givers and patients.
Patents: DD17052- FR1663028: “Procedure for counting particles in a sample by lens-free imaging”
####
About Leti
Leti, a technology research institute at CEA, is a global leader in miniaturization technologies enabling smart, energy-efficient and secure solutions for industry. Founded in 1967, CEA-Leti pioneers micro-& nanotechnologies, tailoring differentiating applicative solutions for global companies, SMEs and startups. CEA-Leti tackles critical challenges in healthcare, energy and digital migration. From sensors to data processing and computing solutions, CEA-Leti’s multidisciplinary teams deliver solid expertise, leveraging world-class pre-industrialization facilities. With a staff of more than 1,900, a portfolio of 3,100 patents, 10,000 sq. meters of cleanroom space and a clear IP policy, the institute is based in Grenoble, France, and has offices in Silicon Valley and Tokyo. CEA-Leti has launched 65 startups and is a member of the Carnot Institutes network. Follow us on www.leti-cea.com and @CEA_Leti.
About HORIBA Medical
HORIBA Medical offers an extensive and comprehensive line of hematology, coagulation and clinical chemistry solutions (including reagents) for in vitro diagnostics. The HORIBA Medical brand has earned the trust of a wide customer base through the quality and reliability of its products. Today, over 30,000 laboratories around the world use HORIBA Medical solution (more information at: www.horiba.com).
For more information, please click here
Contacts:
Press Contact HORIBA Medical
Carole Barascud
Public and Media Relations
Tel. +33.4.67.14.15.59
Press Contact CEA-Leti
Agency
Tel. +33 6 74 93 23 47
Copyright © Leti
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Chemistry
Breaking carbon–hydrogen bonds to make complex molecules November 8th, 2024
Imaging
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Possible Futures
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Discoveries
Breaking carbon–hydrogen bonds to make complex molecules November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
Research partnerships
Gene therapy relieves back pain, repairs damaged disc in mice: Study suggests nanocarriers loaded with DNA could replace opioids May 17th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Researchers’ approach may protect quantum computers from attacks March 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||